Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Gross Profit (2017 - 2025)

Historic Gross Profit for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.8 million.

  • Aclaris Therapeutics' Gross Profit fell 2521.67% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 4446.18%. This contributed to the annual value of $15.9 million for FY2024, which is 4275.86% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Gross Profit of $2.8 million as of Q3 2025, which was down 2521.67% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Gross Profit ranged from a high of $18.1 million in Q3 2022 and a low of $298000.0 during Q1 2022
  • Moreover, its 5-year median value for Gross Profit was $1.6 million (2024), whereas its average is $4.0 million.
  • In the last 5 years, Aclaris Therapeutics' Gross Profit soared by 313125.0% in 2022 and then tumbled by 5622.48% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Gross Profit (Quarter) stood at $352000.0 in 2021, then soared by 1853.41% to $6.9 million in 2022, then skyrocketed by 144.98% to $16.8 million in 2023, then crashed by 49.5% to $8.5 million in 2024, then crashed by 67.54% to $2.8 million in 2025.
  • Its Gross Profit was $2.8 million in Q3 2025, compared to $1.3 million in Q2 2025 and $949000.0 in Q1 2025.